2026 BD opportunity scan for CanWell Pharma Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Caliway Biopharmaceuticals Co. Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach ra

2026 BD opportunity scan for BrightPath Biotherapeutics Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach r

2026 BD opportunity scan for Breathe Biologics Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Brainfarma Indústria Química e Farmacêutica SA: pipeline stage, evidence package, IP risk, deal precedent, financial signals and

2026 BD opportunity scan for Biosios (Beijing) Biotechnology Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outre

2026 BD opportunity scan for BioNova Pharmaceuticals (Shanghai) Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreac

2026 BD opportunity scan for Biocad CJSC: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Bio-Thera Solutions, Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Bharat Biotech International Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rati

2026 BD opportunity scan for Benuvia Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Beijng Immunoah Pharma Tech Co., Ltd: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach r